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Objective: The impact of obesity on ventricular remodeling after myocardial infarction (MI) is still
poorly understood. Therefore, the aim of this study was to evaluate the role of waist circumference
(WC) and body mass index as predictors of cardiac remodeling in patients after an anterior MI.
Methods: Eighty-three consecutive patients with anterior MI were prospectively evaluated. Clinical
characteristics and echocardiographic data were analyzed at admission and at a 6-mo follow-up.
Ventricular remodeling was deﬁned as a 10% increase in left ventricular end-systolic or end-
diastolic diameter at the 6-mo follow-up.
Results: In our study, 83 consecutive patients were evaluated (72% men). Ventricular remodeling
was present in 31% of the patients (77% men). Patients with remodeling had higher creatine
phosphokinase and creatine phosphokinase-MB peak values, a higher resting heart rate, a larger
left atrial diameter, and a larger interventricular septum diastolic thickness. In addition, patients
with remodeling had lower peak velocity of early ventricular ﬁlling deceleration time and ejection
fraction. Patients with remodeling presented higher WC values (with remodeling, 99.2  10.4 cm;
without remodeling, 93.9  10.8 cm, P ¼ 0.04), but there were no differences in the body mass
index values. In the logistic regression analysis, WC, adjusted by age, gender, ejection fraction, and
creatine phosphokinase levels, was an independent predictor of left ventricular remodeling (odds
ratio 1.067, 95% conﬁdence interval 1.001–1.129, P ¼ 0.02).
Conclusion: Waist circumference, but not body mass index, is a predictor of ventricular remodeling
after an anterior MI. Therefore, the WC of these patients should be measured in clinical practice.
 2013 Elsevier Inc. All rights reserved.Introduction
Myocardial infarction (MI) has been associated with an
increased number of hospitalizations and deaths around the
world [1,2]. The prognosis after an MI has been related to several
factors, including age, gender, heart rate, cardiogenic shock,
infarct size, previous infarct, type 2 diabetes, hypertension,
decreased ejection fraction, and signs of heart failure [3–6]. In
recent years, another variable studied as a predictor of poor
outcome after an MI has been ventricular remodeling [7].
Considering the relation between remodeling and outcomes,
in the acute phase after MI, ventricular remodeling has been
associated with ventricular rupture, aneurysmal formation, andchool.
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ll rights reserved.complex ventricular arrhythmias. Similarly, chronic ventricular
remodeling has been shown to play a key role in the patho-
physiology of ventricular dysfunction [8,9]. Taking into consid-
eration that the course of remodeling can be modiﬁed through
several therapeutic interventions, several strategies have been
used to predict the remodeling process.
Obesity has been well established as a risk factor for cardio-
vascular diseases [10]. However, the impact of obesity on
ventricular remodeling and on outcomes after an MI is still
poorly understood. Obesity has been independently associated
with poor outcomes after an MI in some studies [11] but not in
others [12–14]. In contrast, different reports have demonstrated
a possible protective effect of obesity on outcomes (the “obesity
paradox”) [15–17].
In addition, taking into account the relation between excess
adiposity and the adverse health consequences, several recent
studies have demonstrated that anthropometric measurements
Table 1
Demographic, clinical, and laboratory data
Variables Left ventricular remodeling P
No (n ¼ 57) Yes (n ¼ 26)
Age (y) 59.7  13.0 54.9  9.8 0.10
Men 70 (40) 77 (20) 0.71
SR 56 (32) 69 (18) 0.37
DM 28 (16) 27 (7) 0.88
Dyslipidemia 77 (44) 76 (20) 0.80
Smoking 40 (23) 46 (12) 0.80
BMI (kg/m2) 26.7  4.52 28.0  3.68 0.21
WC (cm) 93.9  10.8 99.2  10.4 0.04
CK (U/L) 1566 (1017–4623) 6168 (3593–8805) <0.001
CK-MB (U/L) 199.0 (135.5–495.3) 514.5 (300.0–721.0) 0.002
BMI, body mass index; CK, creatine phosphokinase; CK-MB, creatine
phosphokinase-MB; DM, diabetes mellitus; SR, systemic hypertension; WC,
waist circumference
Data are expressed as mean  SD, percentage (number), or median (lower and
upper quartiles).
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diabetes [18], cardiovascular diseases [19,20] and left ventricular
(LV) diastolic dysfunction [21] than an index of general adiposity,
such as the body mass index (BMI).
Importantly, the role of obesity in ventricular remodeling
after anMI is unknown. Therefore, the objective of this studywas
to evaluate the role of waist circumference (WC) and BMI as
predictors of cardiac remodeling in patients after an anterior MI.
Material and methods
All procedures were approved by the ethics committee of our institution, and
all participants provided their written consent.
Study design
We used the formula by Fisher and Belle [22] for the sample size estimation,
with the following variables: a ventricular remodeling prevalence of 30% to 60%,
a 95% conﬁdence interval, and a sample error of 10%. The result was 81 patients.
Therefore, from December 2008 to July 2010, 94 consecutive patients with an
anterior MI were studied. The exclusion criteria were active malignancy; infec-
tion; end-stage cardiac, pulmonary, or hepatic disease; pregnancy; an age
younger than 18 y; atrial ﬁbrillation; a previous MI; and valve disease. Three
patients did not agree to participate, three patients were excluded because of an
atrial ﬁbrillation, and ﬁve patients died. Therefore, 83 patients were prospec-
tively evaluated.
On admission, patient characteristics, including WC, BMI, age, gender, heart
rate, cardiovascular risk factors, concomitant diseases, medical treatment,
admission symptoms, and prehospital delay, were recorded. The BMI was
calculated as body weight in kilograms divided by height in meters square. WC
was measured at the umbilicus level, while the patient was standing, at end
expiration [23]. Body height wasmeasured using a stadiometer; bodyweightwas
measured using calibrated scales (Filizola, S~ao Paulo, Brazil).
An echocardiographic assessment was completed during the index hospi-
talization (approximately 3–5 d after admission) and at the 6-mo follow-up. After
the echocardiographic analysis, the patients were divided into two groups: those
with and those without ventricular remodeling.
Deﬁnitions
Acute MI was diagnosed in the presence of the two following criteria:
persistent angina pectoris for at least 20 min and an ST-segment elevation of at
least 2 mm in at least two contiguous precordial leads or the presence of a left
bundle branch block. An acute MI was later conﬁrmed by the increase of cardiac
enzymes to more than twice the upper limit of the normal range [24]. The infarct
size was determined using the creatine phosphokinase and creatine
phosphokinase-MB values.
The deﬁnition of diabetes mellitus was based on clinical features and a fasting
glucose level of at least 126mg/dL on two separate occasions or ongoing treatment
of the disease. According to the Seventh Report of the Joint National Committee on
the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,
systemic hypertension was deﬁned as a systolic blood pressure higher than
140 mmHg and/or a diastolic blood pressure higher than 90 mmHg [25]. Dyslipi-
demia was identiﬁed according to the National Cholesterol Education Program
Adult Treatment Panel III guidelines as total cholesterol levels of at least 200mg/dL,
a high-density lipoprotein level lower than 40 mg/dL for men and lower than
50 mg/dL for women, or a triacylglycerol level of at least 150 mg/dL [26].
Ventricular remodeling was deﬁned as a 10% increase in LV end-systolic or
end-diastolic diameter at the 6-mo follow-up [27].
Echocardiographic analysis
The echocardiograph was an HDI 5000 Sono model (Philips Medical Systems,
Bothell, WA, USA) equipped with a 2.0- to 4.0-MHz probe capable of acquiring
second harmonic, tissue, pulsed, continuous, and color Doppler and one- and two-
dimensional mode images. With subjects positioned in the left lateral decubitus
position and monitored with an electrocardiographic lead, the following echo-
cardiographic views were obtained: the parasternal short-axis view to measure
the ventricles, the aorta, and left atrium and the apical two-, four-, and ﬁve-
chamber views to evaluate the cavities and the systolic and diastolic functions
of the ventricles. All measurements were performed in accordance with the
American Society of Echocardiography/European Association of Echocardiog-
raphy [28] recommendations. The average of three measurements was calculated
for each variable. Three operators assessed the echocardiograms. However, for
each patient, the same operator assessed the echocardiogram at baseline and after6 mo. Intraobserver and interobserver variabilities were lower than 3% and lower
than 5%, respectively.
Left ventricular systolic function was evaluated by measuring the ejection
fraction according to the Simpsonmethod. LV diastolic functionwas evaluated by
measuring the early and late diastolic mitral inﬂow velocities, the ratio between
the two diastolic mitral inﬂow velocities, the early diastolic mitral inﬂow velocity
deceleration time, and the isovolumic relaxation time.
Statistical analysis
The data are expressed as mean  standard deviation or median (lower and
upper quartiles). Statistical comparisons for continuous variables between the
groups were performed with Student’s t test for parameters with a normal
distribution, which was assessed by the Kolmogorov–Smirnov test. Otherwise,
comparisons between the groups were completed with the Mann–Whitney U
test. Comparisons between baseline and 6 mo were performed by the paired t
test. For categorical data, chi-square tests were performed. To adjust BMI andWC
by gender and age, we used analysis of covariance. The logistic regression was
used for the remodeling prediction. The calibration of the model was assessed by
the Hosmer–Lemeshow statistic. Data analysis was completed with SigmaStat
2.03 for Windows v2.03 (SPSS, Inc., Chicago, IL, USA). P < 0.05 was considered
statistically signiﬁcant.Results
Demographic, clinical, and laboratory data are presented in
Table 1. Eighty-three consecutive patients were evaluated; 72%
were men. Ventricular remodeling was present in 31% of the
patients. A large proportion of patients had systemic hyperten-
sion and dyslipidemia (approximately 60% and 77%, respectively)
Type 2 diabeteswas present in 27% of the patients. Therewere no
differences in these comorbidities between the two groups.
Patients with remodeling presented larger WC values than
patients without remodeling (P¼ 0.04). In contrast, there was no
difference in the BMI between the groups (P ¼ 0.21; Table 1). A
comparison of the BMI and WC values when separated by male
and female subjects showed no differences (Table 2).
The infarct size was larger in the remodeling group (Table 1).
Reperfusion therapy was performed in 88% of the patients, and
approximately 69% of patients underwent primary angioplasty
(a Thrombolysis In Myocardial Infarction ﬂow grade 2 was
present in 96% of these patients; Table 3). In addition, all patients
received acetylsalicylic acid (ASA) and clopidogrel. Patients in
the left ventricular remodeling group used more spironolactone
(P ¼ 0.007) than the group without remodeling (Table 3).
The initial echocardiographic analysis demonstrated a greater
interventricular septal diastolic thickness and a larger left atrial
diameter in the remodeling group (Table 4). In addition, patients
Table 2
BMI and WC separated by gender
Variables Left ventricular remodeling P
No Yes
WC in men 94.1  10.8 (40) 100.2  10.0 (20) 0.039
WC women 93.7  10.9 (17) 96.0  12.2 (6) 0.670
BMI in men 26.6  4.5 (40) 27.8  3.5 (20) 0.301
BMI in women 27.0  4.6 (17) 28.8  4.6 (6) 0.419
BMI, body mass index; WC, waist circumference
Data are expressed as mean  SD (number).
Table 4
Echocardiographic data (3 to 5 d after admission)
Variables Left ventricular remodeling P
No (n ¼ 57) Yes (n ¼ 26)
LA (mm) 39.0 (38.0–43.0) 44.5 (39.5–47.0) 0.01
LVEDD (mm) 50.0 (48.0–52.0) 48.9 (44.9–55.6) 0.59
LVSD (mm) 34.0 (31.0–37.0) 32.3 (29.2–40.9) 0.39
IVS (mm) 10.0 (9.0–11.1) 11.0 (10.0–13.0) 0.05
LVWT (mm) 10.3 (9.8–11.0) 11.0 (9.9–11.7) 0.15
2  LVWT/LVEDD 0.41 (0.38–0.47) 0.42 (0.39–0.49) 0.17
E wave (cm/s) 62.4  15.6 65.6  19.4 0.43
A wave (cm/s) 77.7  15.5 74.2  19.5 0.38
E/A wave 0.78 (0.66–0.88) 0.81 (0.63–1.26) 0.57
IVRT (ms) 116 (108–128) 108 (92–125) 0.20
EDT (ms) 238  54.3 178  59.6 <0.001
HR (beats/min) 72.6  11.4 82.7  13.5 0.001
EF (%) 48 (43.3–57.7) 38 (35.0–50.0) <0.001
A wave, peak velocity of transmitral ﬂow during atrial contraction; EDT, peak
velocity of early ventricular ﬁlling deceleration time; EF, ejection fraction; E
wave, peak velocity of early ventricular ﬁlling; HR, heart rate; IVRT, iso-
volumetric relaxation time; IVS, interventricular septum; LA, left atrium; LVEDD,
left ventricular end-diastolic dimension; LVSD, left ventricular systolic dimen-
sion; LVWT, left ventricular posterior wall thickness
Data are expressed as mean  SD or median (lower and upper quartiles).
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diogram, a higher heart rate and worse diastolic and systolic
functions compared with the no-remodeling group. The echo-
cardiographic data at baseline and after the 6-mo follow-up are
listed in Table 5. The MI induced increased left atrial and LV
volumes and isovolumic relaxation time. In contrast, the ejection
fraction increased during the 6-mo period.
An analysis of the mean BMI value demonstrated that the
patients in the two groups were overweight; however, there was
no difference in the BMI values between the groups. WC was
larger in patients with LV remodeling (P ¼ 0.04; Table 1). In the
multiple logistic regression, when adjusted for age, gender,
ejection fraction, and creatine phosphokinase-MB levels, WC
remained an independent predictor of LV remodeling (Table 6).
Discussion
This study aimed to evaluate the role of WC and BMI as
predictors of cardiac remodeling in patients after an anterior MI.
Interestingly, only WC, an anthropometric measurement of
central obesity, predicted LV remodeling in these patients.
After an MI, myocyte necrosis and the resultant abrupt
increase in loading conditions trigger a cascade of biochemical
intracellular signal processes that modulate reparative changes
at the infarction site and in the non-infarcted myocardium [29].
Changes in the ventricular mass, volume, and geometry are
characteristic features of ventricular remodeling. Although
ventricular remodeling initially can be a compensatory process,
ventricular remodeling eventually leads to progressive ventric-
ular dysfunction, heart failure, and sudden death [8,9].
Thus, the identiﬁcation of factors that inﬂuence ventricular
remodeling is essential for early treatment. Several factors, suchTable 3
Medication data during hospitalization
Variables Left ventricular remodeling P
No (n ¼ 57) Yes (n ¼ 26)
FT 16 (9) 19 (5) 0.76
PA 65 (37) 77 (20) 0.40
ASA 100 (57) 100 (26) 1.00
Clopidogrel 100 (57) 100 (26) 1.00
GPI 47 (27) 65 (17) 0.20
UFH 26 (15) 15 (3) 0.22
Clexane 77 (44) 88 (23) 0.36
ACEI 91 (52) 96 (25) 0.66
ARB 3.5 (2) 3.8 (1) 1.00
b-Blockers 98 (56) 92 (24) 0.23
Nitrates 26 (15) 34 (9) 0.61
Spironolactone 10 (6) 38 (10) 0.007
Statins 96 (55) 100 (26) 1.00
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; ASA, acetylsalicylic acid; FT, ﬁbrinolytic therapy; GPI, glycoprotein IIb/
IIIa inhibitor; PA, primary angioplasty; UFH, unfractionated heparin
Values are presented as percentage (number).as recurrent myocardial ischemia, infarct size, pre-existing
comorbidities, and ejection fraction, inﬂuence the appearance
of LV remodeling and cardiac dysfunction with or without clin-
ical heart failure after an MI [8,9]. In the present study, most
patients were men, and there was a high frequency of systemic
hypertension and dyslipidemia, most likely due to the speciﬁc
population, with an anterior MI. However, gender or pre-existing
comorbidities were not predictors of ventricular remodeling.
Considering the prevalence of ventricular remodeling in our
study, it is interesting to note that 31% of the patients had
remodeling despite the high rates of successful reperfusion
therapy and standard care. Moreover, patients in the remodeling
group already exhibited higher heart rates and worse diastolic
and systolic dysfunctions on their ﬁrst echocardiogram
compared with the no-remodeling group. These early signs of
ventricular dysfunction in the remodeling groupmay explain the
greater use of spironolactone in these patients.
In recent years, a substantial body of evidence has demon-
strated a harmful effect of excess adiposity on the cardiovascular
system. Given the simplicity of the BMI as a measurement, it hasTable 5
Echocardiographic data at baseline and after 6 mo
Variables Period P
Baseline 6 mo
LA (mm) 40.0 (36.0–45.0) 41.0 (39.0–45.0) <0.001
LVEDD (mm) 50.0 (47.0–53.0) 51.3 (48.0–54.9) <0.001
LVSD (mm) 33.0 (30.0–37.0) 35.3 (31.0–38.9) 0.002
IVS (mm) 10.0 (9.0–12.0) 10.0 (9.0–11.0) 0.100
LVWT (mm) 10.7 (9.4–11.4) 10.0 (9.2–11.0) 0.005
2  LVWT/LVEDD 0.42 (0.38–0.47) 0.39 (0.35–0.43) <0.001
E/A 0.79 (0.66–0.91) 0.80 (0.68–1.08) 0.186
IVRT (ms) 116 (100–125) 120 (112–132) 0.008
EDT (ms) 216  59.5 227  65.0 0.062
EF (%) 46  10 48  10 0.034
E/A, peak velocity of early ventricular ﬁlling/peak velocity of transmitral ﬂow
during atrial contraction; EDT, peak velocity of early ventricular ﬁlling deceler-
ation time; EF, ejection fraction; IVRT, isovolumetric relaxation time; IVS,
interventricular septum; LA, left atrium; LVEDD, left ventricular end-diastolic
dimension; LVSD, left ventricular systolic dimension; LVWT, left ventricular
posterior wall thickness
Data are expressed as mean  SD or median (lower and upper quartiles).
Table 6
Logistic regression analysis forWC and BMI values as predictors of left ventricular
remodeling
OR 95% CI P
WC (cm) 1.048 1.001–1.097 0.04
WC (cm)* 1.067 1.009–1.129 0.02
BMI (kg/m2) 1.074 0.962–1.200 0.21
BMI (kg/m2)* 1.100 0.951–1.273 0.20
BMI, body mass index; CI, conﬁdence ratio; OR, odds ratio; WC, waist
circumference
* Adjusted for age, gender, ejection fraction, and creatine phosphokinase-MB
levels.
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a screening in the initial clinical assessment of obesity. Never-
theless, the BMI presents a poor sensitivity to reﬂect body
fatness, given the fact that obesity is deﬁned according to the fat
percentage and not to body weight. Conversely, WC has been
shown to be a simple and effective way to assess central obesity,
with a good correlation with abdominal image and a strong
associationwith cardiovascular risk [23]. However, the exact role
of the BMI and WC as predictors of cardiac remodeling after an
MI remains to be elucidated.
It is important to note that BMI values were not signiﬁcantly
different between the groups, although the BMI mean values
were higher than 25 kg/m2 in the two groups. Obesity has been
known since 1965 to induce cardiac remodeling [30]; however,
its inﬂuence on ventricular remodeling after an anterior MI had
not been previously evaluated. Obesity has been linked to
a spectrum of cardiac changes, and the primary feature was
thought to be chronic volume overload owing to the high cardiac
output and eccentric hypertrophy [31]. However, recent studies
have reported that obesity is most often associated with
concentric LV remodeling, normal LV ejection fraction, and
subclinical abnormalities of systolic and diastolic functions.
Moreover, there is little evidence that these abnormalities are
progressive [32,33].
Taking into account the relation between excess adiposity and
the adverse health consequences, epidemiologic and clinical
studies have also demonstrated that obesity is associated with
contradictory outcomes after an MI. Despite several pathophys-
iologic pathways by which obesity increases the risk of coronary
artery disease and adverse cardiovascular events, some studies
have demonstrated a lack of association between obesity and
cardiovascular death [15–17]. This “obesity paradox” may be
related to a lower lean body mass associated with lower or
normal BMI values, a lack of secondary prevention therapies in
patients with normal BMI values, and the inability of BMI values
to adequately reﬂect adiposity [17].
In accordance with these assumptions, recent studies have
demonstrated that anthropometric measurements related to
central obesity are more sensitive predictors of comorbidities
and cardiovascular risk than an index of general adiposity, such
as the BMI [18–21]. This study reinforces the differences between
WC and BMI values and suggests that, at least for the prediction
of LV remodeling after an MI, anthropometric measurements
related to central obesity should be used. Even when WC was
adjusted for infarct size, systolic function, age, and gender, it
remained an independent predictor of LV remodeling after anMI.
Several studies have suggested that visceral, but not subcuta-
neous fat, is associated with the synthesis of proinﬂammatory
adipokines and increased levels of reactive oxygen species derived
from reduced nicotinamide adenine dinucleotide phosphate
oxidase activity [34,35]. Interestingly, WC is an anthropometricmeasurement of central obesity that is related to visceral fat. Thus,
inﬂammation and oxidative stress are potential explanations for
the independent relationbetweenWCandventricular remodeling
after an anterior MI. Further studies are required to investigate
these hypotheses.
We should considerer the major limitations of this study. Our
study included a small sample. Indeed, the odds ratio for the BMI
was not signiﬁcant, probably because of the small sample and
low statistical power. In addition, selection bias is a major source
of errors and our study included patients from a single medical
center. Nevertheless, we believe that our study adds important
data about obesity variables and ventricular remodeling after an
anterior MI.
In conclusion, our data indicate that WC, but not BMI, is
a predictor of ventricular remodeling after an anterior MI.
Therefore, in these patients, WC should be measured in clinical
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